Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT07197307

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:27:14.392041+00:00

Published At

2025-09-29T00:00:00+00:00

Record Updated At

2025-09-29

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Aggressive Diffuse Large B-cell Lymphoma", "High-grade B-cell Lymphoma (HGBL)", "Follicular Lymphoma (FL) Grade 3B"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2025-09-29"

protocolSection.identificationModule.nctId

"NCT07197307"

protocolSection.identificationModule.officialTitle

"Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)"

protocolSection.statusModule.overallStatus

"NOT_YET_RECRUITING"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Aggressive Diffuse Large B-cell Lymphoma (protocolSection.conditionsModule.conditions)
• High-grade B-cell Lymphoma (HGBL) (protocolSection.conditionsModule.conditions)
• Follicular Lymphoma (FL) Grade 3B (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.